{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:46:54Z","timestamp":1790952414469,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P50DA054072"],"award-info":[{"award-number":["P50DA054072"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA035165"],"award-info":[{"award-number":["T32DA035165"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA052975"],"award-info":[{"award-number":["R01DA052975"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA052627-02"],"award-info":[{"award-number":["K23DA052627-02"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA055087"],"award-info":[{"award-number":["K23DA055087"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low-threshold care (LTC) practices for prescribing medication for opioid use disorder (MOUD) systematically remove treatment barriers, increasing access to lifesaving MOUD. Despite its promise, LTC operationalization is unclear and heterogeneous, and lacks standardized measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and test LTC composite measures as useful predictors of implementation outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This prospective cohort study was embedded within a California state MOUD practice change collaborative involving safety-net primary care clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Data were collected at baseline, midpoint, and endpoint from 20 clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Clinics received a multifaceted implementation\u2013support package designed to improve MOUD delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Measures<\/jats:title>\n                    <jats:p>Four LTC scales (LTC12, LTC5, LTC3, LTC2) were developed and tested using team-reported one to five Likert items. Implementation outcomes included Reach (monthly new MOUD patients), Retention (monthly new MOUD patients engaged in treatment after initial diagnosis), and Adoption (active MOUD prescribers). Analyses included repeated-measures ANOVA for LTC change and Poisson GEE for incidence rate ratios, adjusting for panel size, medically underserved area designation, and time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>\n                      Clinics showed significant improvements in LTC scores over time. The LTC12 scale demonstrated the largest effect size (\n                      <jats:italic>d<\/jats:italic>\n                      \u2009=\u20091.18,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.003). A 1-point increase on the LTC3 index was associated with a 37% increase in new patients receiving MOUD (IRR\u2009=\u20091.37, 95% CI [1.01,1.86],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.047). A 1-point increase on LTC2 was associated with a 24% increase (IRR\u2009=\u20091.24, 95% CI [1.01,1.53],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009= 0.049).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings provide preliminary empirical support for a replicable measure of LTC in primary care settings. Longer scales showed greater internal consistency and sensitivity to change, while brief scales predicted patient reach outcomes. These measures may be useful for clinical programs to gauge the extent to which their MOUD services align with low threshold care principles and to guide quality improvement efforts. Future research should validate these scales in larger, diverse cohorts and test causal impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-10112-9","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:22:45Z","timestamp":1768422165000},"page":"2437-2447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Implementation Outcomes of Low Threshold Care for Persons with Opioid Use Disorders"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3182-6131","authenticated-orcid":false,"given":"Wayne","family":"Kepner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rosenberg-Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"2","key":"10112_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95-98.","journal-title":"J Addict Med."},{"key":"10112_CR2","doi-asserted-by":"publisher","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. Natl Cent Health Stat. 2025. https:\/\/doi.org\/10.15620\/cdc\/20250305008.","DOI":"10.15620\/cdc\/20250305008"},{"issue":"8","key":"10112_CR3","doi-asserted-by":"publisher","first-page":"e2327488","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488-e2327488.","journal-title":"JAMA Netw Open."},{"key":"10112_CR4","unstructured":"White W, Galanter M, Kolodner G, Kepner W, Sarapas C, Mouton CL. Medications for Opioid Use Disorder: Enhancing Retention to Achieve Long-term Remission and Recovery. Chesnut Health Syst Lighthouse Inst. 2025."},{"key":"10112_CR5","unstructured":"White WL. Slaying the dragon: The history of addiction treatment and recovery in America. 1998."},{"key":"10112_CR6","unstructured":"Substance Abuse and Mental Health Services Administration. Low Barrier Models of Care for Substance Use Disorders. (PEP23\u201302\u201300\u2013005). 2023. Rockville, MD: Substance Abuse and Mental Health Services Administration Retrieved from https:\/\/library.samhsa.gov\/sites\/default\/files\/advisory-low-barrier-models-of-care-pep23-02-00-005.pdf"},{"issue":"1","key":"10112_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13722-022-00342-1","volume":"17","author":"J Carter","year":"2022","unstructured":"Carter J, Li Z, Chen H, Greiner M, Bush C, Bhattacharya D, Poley S, Sachdeva N, Crowder JC, Feigal J. Low barrier medication for opioid use disorder at a federally qualified health center: A retrospective cohort study. Addict Sci Clin Pract. 2022;17(1):60. https:\/\/doi.org\/10.1186\/s13722-022-00342-1.","journal-title":"Addict Sci Clin Pract."},{"key":"10112_CR8","doi-asserted-by":"publisher","first-page":"103715","DOI":"10.1016\/j.drugpo.2022.103715","volume":"105","author":"AK Gertner","year":"2022","unstructured":"Gertner AK, Clare HM, Powell BJ, Gilbert AR, Jones HE, Silberman P, Shea CM, Domino ME. A mixed methods study of provider factors in buprenorphine treatment retention. Int J Drug Policy. 2022;105:103715. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103715.","journal-title":"Int J Drug Policy."},{"issue":"8","key":"10112_CR9","doi-asserted-by":"publisher","first-page":"e2328627","DOI":"10.1001\/jamanetworkopen.2023.28627","volume":"6","author":"EJ Austin","year":"2023","unstructured":"Austin EJ, Chen J, Briggs ES, Ferro L, Barry P, Heald A, Merrill JO, Curran GM, Saxon AJ, Fortney JC. Integrating opioid use disorder treatment into primary care settings. JAMA Netw Open. 2023;6(8):e2328627-e2328627.","journal-title":"JAMA Netw Open."},{"key":"10112_CR10","doi-asserted-by":"crossref","unstructured":"Franz B, Dhanani LY, Bogart S, Fenstemaker C, Miller WC, Hall OT, Brook D, Go V. Different forms of stigma and rural primary care professionals' willingness to prescribe buprenorphine. J Subst Use Addict Treat. 2025;209633.","DOI":"10.1016\/j.josat.2025.209633"},{"key":"10112_CR11","doi-asserted-by":"publisher","first-page":"215013192211122","DOI":"10.1177\/21501319221112272","volume":"13","author":"B Lai","year":"2022","unstructured":"Lai B, Croghan I, Ebbert JO. Buprenorphine waiver attitudes among primary care providers. J Prim Care Commun Health. 2022;13:21501319221112272.","journal-title":"J Prim Care Commun Health."},{"key":"10112_CR12","doi-asserted-by":"publisher","first-page":"215013192412463","DOI":"10.1177\/21501319241246359","volume":"15","author":"SA Marshall","year":"2024","unstructured":"Marshall SA, Siebenmorgen LE, Youngen K, Borders T, Zaller N. Primary Care Providers\u2019 Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic. J Prim Care Commun Health. 2024;15:21501319241246359.","journal-title":"J Prim Care Commun Health."},{"key":"10112_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-017-0072-2","volume":"12","author":"EP Bhatraju","year":"2017","unstructured":"Bhatraju EP, Grossman E, Tofighi B, McNeely J, DiRocco D, Flannery M, Garment A, Goldfeld K, Gourevitch MN, Lee JD. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract. 2017;12:1-10.","journal-title":"Addict Sci Clin Pract."},{"key":"10112_CR14","unstructured":"Kennedy AJ, Wessel CB, Levine R, Downer K, Raymond M, Osakue D, Hassan I, Merlin JS, Liebschutz JM. Factors associated with long-term retention in buprenorphine-based addiction treatment programs: a systematic review. J Gen Int Med. 2022;1\u20139."},{"issue":"1","key":"10112_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1370\/afm.3190","volume":"23","author":"TL Hall","year":"2025","unstructured":"Hall TL, Mendez D, Sobczak C, Mathieu S, Wiggins K, Cebuhar K, Quintana L, Weiss J, Knierim K. Evaluation of a Program Designed to Support Implementation of Prescribing Medication for Treatment of Opioid Use Disorder in Primary Care Practices. Ann Fam Med. 2025;23(1):44-51.","journal-title":"Ann Fam Med."},{"key":"10112_CR16","doi-asserted-by":"publisher","first-page":"108395","DOI":"10.1016\/j.jsat.2021.108395","volume":"126","author":"HC Garneau","year":"2021","unstructured":"Garneau HC, Hurley B, Fisher T, Newman S, Copeland M, Caton L, Cheng H, McGovern MP. The integrating medications for addiction treatment (IMAT) index: a measure of capability at the organizational level. J Subst Abuse Treat. 2021;126:108395.","journal-title":"J Subst Abuse Treat."},{"issue":"1","key":"10112_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s43058-022-00306-1","volume":"3","author":"H Cheng","year":"2022","unstructured":"Cheng H, McGovern MP, Garneau HC, Hurley B, Fisher T, Copeland M, Almirall D. Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes. Implement Sci Commun. 2022;3(1):72.","journal-title":"Implement Sci Commun."},{"key":"10112_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13722-025-00600-y","volume":"20","author":"W Kepner","year":"2025","unstructured":"Kepner W, Vest N, Risner E, et al. Three trajectories of implementation of medications for opioid use disorder in primary care. Addict Sci Clin Pract. 2025;20:69. https:\/\/doi.org\/10.1186\/s13722-025-00600-y.","journal-title":"Addict Sci Clin Pract."},{"issue":"2","key":"10112_CR19","first-page":"147","volume":"12","author":"JC Kleinman","year":"1977","unstructured":"Kleinman JC, Wilson RW. Are\" medically underserved areas\" medically underserved? Health Serv Res. 1977;12(2):147.","journal-title":"Health Serv Res."},{"key":"10112_CR20","unstructured":"Health Resources and Services Administration. Federally Qualified Health Centers. 2017b. Retrieved 5\/30\/2025 from https:\/\/www.hrsa.gov\/opa\/eligibility-and-registration\/health-centers\/fqhc\/index.html."},{"key":"10112_CR21","unstructured":"Health Resources and Services Administration. Federally Qualified Health Center Look-Alike. 2017a. Retrieved 5\/30\/2025 from https:\/\/www.hrsa.gov\/opa\/eligibility-and-registration\/health-centers\/fqhc-look-alikes\/index.html."},{"issue":"6","key":"10112_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/MLR.0b013e31803bb479","volume":"45","author":"D Reeves","year":"2007","unstructured":"Reeves D, Campbell SM, Adams J, Shekelle PG, Kontopantelis E, Roland MO. Combining multiple indicators of clinical quality: an evaluation of different analytic approaches. Med Care. 2007;45(6):489-496.","journal-title":"Med Care."},{"key":"10112_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5116\/ijme.4dfb.8dfd","volume":"2","author":"M Tavakol","year":"2011","unstructured":"Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ. 2011;2:53.","journal-title":"Int J Med Educ."},{"key":"10112_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","volume":"7","author":"RE Glasgow","year":"2019","unstructured":"Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, Ory MG, Estabrooks PA. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64.","journal-title":"Front Public Health."},{"key":"10112_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","volume":"91","author":"AR Williams","year":"2018","unstructured":"Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abus Treat. 2018;91:57-68.","journal-title":"J Subst Abus Treat."},{"key":"10112_CR26","doi-asserted-by":"crossref","unstructured":"Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.","DOI":"10.1093\/biomet\/73.1.13"},{"issue":"11","key":"10112_CR27","first-page":"496","volume":"13","author":"A Nahian","year":"2022","unstructured":"Nahian A, Shepherd JG. Analysis of opioid poisoning in medically underserved rural areas: an evaluation of international statistical classification of diseases codes from the state of South Dakota. J Addict Res Ther. 2022;13(11):496.","journal-title":"J Addict Res Ther."},{"issue":"1","key":"10112_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/atm-20-3623","volume":"4","author":"Z Zhang","year":"2016","unstructured":"Zhang Z. Missing data imputation: focusing on single imputation. Ann Transl Med. 2016;4(1):9.","journal-title":"Ann Transl Med."},{"issue":"394","key":"10112_CR29","first-page":"165","volume":"770","author":"J Allaire","year":"2012","unstructured":"Allaire J. RStudio: integrated development environment for R. Boston, MA. 2012;770(394):165-171.","journal-title":"Boston, MA."},{"issue":"5","key":"10112_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/ADM.0000000000000774","volume":"15","author":"CD Nordeck","year":"2021","unstructured":"Nordeck CD, Buresh M, Krawczyk N, Fingerhood M, Agus D. Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic. J Addict Med. 2021;15(5):364\u2013369. https:\/\/doi.org\/10.1097\/ADM.0000000000000774.","journal-title":"J Addict Med."},{"key":"10112_CR31","doi-asserted-by":"crossref","unstructured":"Snyder H, Kalmin MM, Moulin A, Campbell A, Goodman-Meza D, Padwa H, ..., Herring AA. Rapid adoption of low-threshold buprenorphine treatment at California emergency departments participating in the CA bridge program. Ann Emerg Med. 2021;78(6):759\u2013772.","DOI":"10.1016\/j.annemergmed.2021.05.024"},{"issue":"5","key":"10112_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ajad.12925","volume":"28","author":"CS Lee","year":"2019","unstructured":"Lee CS, Rosales R, Stein MD, Nicholls M, O\u2019Connor BM, Loukas Ryan V, Davis EA. Brief report: Low\u2010barrier buprenorphine initiation predicts treatment retention among latinx and non\u2010latinx primary care patients. Am J Addict. 2019;28(5):409-412.","journal-title":"Am J Addict."},{"issue":"1","key":"10112_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13722-019-0149-1","volume":"14","author":"J Carter","year":"2019","unstructured":"Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addic Sci Clin Pract. 2019;14(1):20.","journal-title":"Addic Sci Clin Pract."},{"key":"10112_CR34","doi-asserted-by":"crossref","unstructured":"Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, ..., Shim MHM. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Subst Abus. 2020;41(3):356\u2013364.","DOI":"10.1080\/08897077.2019.1635557"},{"key":"10112_CR35","doi-asserted-by":"crossref","unstructured":"Jakubowski A, Norton BL, Hayes BT, Gibson BE, Fitzsimmons C, Stern LS, ..., Fox AD. Low-threshold buprenorphine treatment in a syringe services program: program description and outcomes. J Addict Med. 2022.","DOI":"10.1097\/ADM.0000000000000934"},{"issue":"1","key":"10112_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","volume":"20","author":"DL Louie","year":"2019","unstructured":"Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157.","journal-title":"BMC Fam Pract."},{"key":"10112_CR37","doi-asserted-by":"crossref","unstructured":"Winograd RP, Coffey B, Woolfolk C, Wood CA, Ilavarasan V, Liss D, ..., Stringfellow E. To prescribe or not to prescribe?: Barriers and motivators for progressing along each stage of the buprenorphine training and prescribing path. J Behav Health Serv Res. 2023;50(2):165\u2013180.","DOI":"10.1007\/s11414-021-09783-z"},{"key":"10112_CR38","doi-asserted-by":"crossref","unstructured":"Christine PJ, Chahine RA, Kimmel SD, Mack N, Douglas C, Stopka TJ, ..., Larochelle MR. Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements. JAMA Netw Open. 2024;7(8):e2425999.","DOI":"10.1001\/jamanetworkopen.2024.25999"},{"issue":"7","key":"10112_CR39","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1007\/s11606-020-06409-6","volume":"36","author":"SN Kapadia","year":"2021","unstructured":"Kapadia SN, Griffin JL, Waldman J, Ziebarth NR, Schackman BR, Behrends CN. A harm reduction approach to treating opioid use disorder in an independent primary care practice: A qualitative study. J Gen Int Med. 2021;36(7):1898\u20131905.","journal-title":"J Gen Int Med."},{"issue":"4","key":"10112_CR40","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/1468-0009.12165","volume":"93","author":"M Shwartz","year":"2015","unstructured":"Shwartz M, Restuccia JD, Rosen AK. Composite measures of health care provider performance: a description of approaches. Milbank Q. 2015;93(4):788-825.","journal-title":"Milbank Q."},{"key":"10112_CR41","doi-asserted-by":"publisher","first-page":"e51525","DOI":"10.2196\/51525","volume":"11","author":"N Fareed","year":"2024","unstructured":"Fareed N, Olvera RG, Wang Y, Hayes M, Larimore EL, Balvanz P, Langley R, Noel CA, Rock P, Redmond D. Lessons Learned From Developing Dashboards to Support Decision-Making for Community Opioid Response by Community Stakeholders: Mixed Methods and Multisite Study. JMIR Hum Factors. 2024;11:e51525.","journal-title":"JMIR Hum Factors."},{"issue":"1","key":"10112_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.amepre.2024.09.013","volume":"68","author":"MM Ali","year":"2025","unstructured":"Ali MM, Chen J, Novak PJ. Utilization of Buprenorphine for Opioid Use Disorder After the Practitioner Waiver Removal. Am J Prevent Med. 2025;68(1):207-209.","journal-title":"Am J Prevent Med."},{"key":"10112_CR43","doi-asserted-by":"crossref","unstructured":"Aronowitz SV, Zucker N, Thompson M, James R, Clapp J, Mandell D. Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review. Drug Alcohol Depend. 2024;112522.","DOI":"10.1016\/j.drugalcdep.2024.112522"},{"issue":"1","key":"10112_CR44","first-page":"qxad013","volume":"1","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, King C, Dooling BC. Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the United States. Health Aff Sch. 2023;1(1):qxad013.","journal-title":"Health Aff Sch."},{"issue":"6","key":"10112_CR45","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","volume":"39","author":"M Olfson","year":"2020","unstructured":"Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others: Trends in buprenorphine treatment by prescriber specialty-primary care providers, psychiatrists, and addiction medicine specialists. Health Aff. 2020;39(6):984-992.","journal-title":"Health Aff."},{"key":"10112_CR46","doi-asserted-by":"publisher","first-page":"108083","DOI":"10.1016\/j.drugalcdep.2020.108083","volume":"213","author":"DR Roehler","year":"2020","unstructured":"Roehler DR, Guy Jr GP, Jones CM. Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. Drug Alcohol Depend. 2020;213:108083.","journal-title":"Drug Alcohol Depend."},{"key":"10112_CR47","doi-asserted-by":"publisher","first-page":"109933","DOI":"10.1016\/j.drugalcdep.2023.109933","volume":"248","author":"MR Larochelle","year":"2023","unstructured":"Larochelle MR, Jones CM, Zhang K. Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016\u20132021. Drug Alcohol Depend. 2023;248:109933.","journal-title":"Drug Alcohol Depend."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10112-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-10112-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10112-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:06:15Z","timestamp":1782403575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-10112-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10112"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-10112-9","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}